MaxCyte, Inc. Clinical & Commercial Agreement with Kite (5188R)
March 01 2019 - 2:01AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5188R
MaxCyte, Inc.
01 March 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
MaxCyte Announces Multi-Drug Clinical & Commercial
Agreement
with Kite, a Gilead Company
Gaithersburg, Maryland - 01 March 2019: MaxCyte (LSE: MXCT,
MXCS), the global cell-based medicines and life sciences company,
announced today that it has expanded its relationship with Kite, a
Gilead Company, by entering into a multi-drug clinical and
commercial agreement. Under the terms of the agreement, Kite will
use MaxCyte's Flow Electroporation(R) Technology to enable
non-viral cell engineering for development of multiple CAR-T drug
candidates for up to 10 targets.
"We're excited to take our relationship with Kite further into
product development, providing the company the ability to leverage
MaxCyte's versatile cell engineering platform to enable the power
of gene-editing for clinical and commercial development of critical
new CAR-T therapeutics," said Doug Doerfler, President & CEO of
MaxCyte, Inc.
The expansion of the Kite-MaxCyte relationship builds on an
existing research agreement announced in November 2018. Under the
terms of the new license agreement, Kite obtains non-exclusive
clinical and commercial-use rights to MaxCyte's cell engineering
platform to develop CAR-T therapies, and MaxCyte will receive
development and approval milestones and sales-based payments in
addition to other licensing fees.
About MaxCyte
MaxCyte is a clinical-stage global cell-based medicines and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA(TM)
therapies for its own pipeline, with its first drug candidate in a
Phase 1 clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its core business, MaxCyte
leverages its Flow Electroporation(R) Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, with all of the top ten
global biopharmaceutical companies, has more than 70 partnered
program licenses in cell therapy including more than 35 licensed
for clinical use. With its robust delivery technology platform,
MaxCyte helps its partners to unlock the full potential of their
products. For more information, visit www.maxcyte.com.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRLFFEFFFITFIA
(END) Dow Jones Newswires
March 01, 2019 02:01 ET (07:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Oct 2023 to Oct 2024